About Bio-Path
Overview
Leadership
Board of Directors
Scientific Advisory Board
Partnering Opportunities
Technology
Pipeline
Pipeline
Prexigebersen
BP1001-A
BP1002
BP1003
Patients
Investors
Overview
SEC Filings
Corporate Governance
Media
Press Releases
Events
Presentations & Publications
Careers
Contact Us
SEC Form 8-K: Press Release dated November 15, 2023
BPTH_Form_8-K_Q3_Earnings_Release
SEC Form 10-Q for Period ending September 30, 2023
BPTH_Form_10-Q_Q3_2023
SEC Form 8-K: Press Release dated October 24, 2023
BPTH_Form_8-K_PR_10-24-2023
SEC Form 8-K: Nasdaq Notice of Noncompliance
BPTH_Form-8-K_Nasdaq_Notice_of_Noncompliance
SEC Form 8-K: Second Quarter 2023 Earnings Release
BPTH_Form_8-K_Q2-2023_Earnings_Release
SEC Form 10-Q for Period ending June 30, 2023
BPTH_20230814_10-Q
SEC Form 8-K: Item 1.01 Entry Into a Material Definitive Agreement
BPTH_8-K_20230809
SEC Form 424B3: Prospectus Supplement dated August 7, 2023
BPTH_424B3_20230809
SEC Form 424B4: Prospectus
BPTH_424B4_20230809
SEC Form S-1/A – Amendment No. 2
Amendment_No_2_to_Form_S-1_20230802
About Bio-Path
Overview
Leadership
Board of Directors
Scientific Advisory Board
Partnering Opportunities
Technology
Pipeline
Pipeline
Prexigebersen
BP1001-A
BP1002
BP1003
Patients
Investors
Overview
SEC Filings
Corporate Governance
Media
Press Releases
Events
Presentations & Publications
Careers
Contact Us